Objective: To evaluate the sensitivity and specificity of the BD SurePath™ liquid-based Papanicolaou test for assessing the cytology of intrauterine endometrial samples according to newly devised cytological diagnostic criteria and a novel descriptive reporting format. Materials and Methods: One hundred and twenty-two endometrial samples were analyzed. All samples were obtained directly from the intrauterine cavity using the Uterobrush or Honest Super Brush. The samples used for the histological examination and cytological tests were collected simultaneously. Our study group devised new cytological diagnostic criteria for examining endometrial samples: the Osaki Study Group method. In this study, histological diagnosis was considered to be the gold standard for cytological diagnosis. A novel descriptive reporting format was also used. Results: Satisfactory cytological specimens were obtained in all cases. The sensitivity and specificity of the SurePath endometrial cytological examination method were 96.4 and 100%, respectively. Conclusion: These results indicate that the SurePath method is acceptable for clinical use. Since the SurePath method seems to be easier and allows greater preparation standardization than the conventional method, coupling it with our newly devised cytological diagnostic criteria and descriptive reporting format might represent a reliable diagnostic method for assessing endometrial specimens.

Keywords:
Endometrial cytology, Intrauterine sampling, Osaki Study Group, Pilot study, SurePath™
1.
Norimatsu Y, Sakamoto S, Ohsaki H, Ozaki S, Yokoyama T, Shimizu K, Yanoh K, Akiyama M, Bamba M, Kobayashi TK: Cytologic features of the endometrial adenocarcinoma: comparison of ThinPrep and BD SurePath preparations. Diagn Cytopathol 2013;41:673-681.
2.
Norimatsu Y, Sakamoto S, Ohsaki H, Ozaki S, Yokoyama T, Shimizu K, Kobayashi TK: Comparison of cytologic features in three methods of LBC in the endometrial carcinoma (in Japanese). Jpn J Med Tech 2013;64:381-388.
3.
Norimatsu Y, Ohsaki H, Yanoh K, Kawanishi N, Kobayashi TK: Expression of immunoreactivity of nuclear findings by p53 and cyclin A in endometrial cytology: comparison with endometrial glandular and stromal breakdown and endometrioid adenocarcinoma grade 1. Diagn Cytopathol 2013;41:303-307.
4.
Yanoh K, Hirai Y, Sakamoto A, Aoki D, Moriya T, Hiura M, Yamawaki T, Shimizu K, Nakayama H, Sasaki H, Tabata T, Ueda M, Udagawa Y, Norimatsu Y: New terminology for intrauterine endometrial samples: a group study by the Japanese Society of Clinical Cytology. Acta Cytol 2012;56:233-241.
5.
Shimizu K, Norimatsu Y, Kobayashi TK, Ogura S, Miyake Y, Ohno E, Sakurai T, Moriya T, Sakurai M: Endometrial glandular and stromal breakdown, part 1: cytomorphological appearance. Diagn Cytopathol 2006;34:609-613.
6.
Norimatsu Y, Shimizu K, Kobayashi TK, Moriya T, Kaku T, Tsukayama C, Miyake Y, Ohno E: Endometrial glandular and stromal breakdown, part 2: cytomorphology of papillary metaplastic changes. Diagn Cytopathol 2006;34:665-669.
7.
Norimatsu Y, Yuminamochi T, Shigematsu Y, Yanoh K, Ikemoto R, Masuno H, Murakami M, Kobayashi TK: Endometrial glandular and stromal breakdown, part 3: cytomorphology of ‘condensed cluster of stromal cells'. Diagn Cytopathol 2009;37:891-896.
8.
Norimatsu Y, Kawai M, Kamimori A, Yuminamochi T, Ohsaki H, Yanoh K, Kawanishi N, Kobayashi TK: Endometrial glandular and stromal breakdown, part 4: cytomorphology of ‘condensed cluster of stromal cells including a light green body'. Diagn Cytopathol 2012;40:204-209.
9.
Demirkiran F, Yavuz E, Erenel H, Bese T, Arvas M, Saniohlu C: Which is the best technique for endometrial sampling? Aspiration (pipelle) versus dilatation and curettage (D&C). Arch Gynecol Obstet 2012;286:1277-1282.
10.
Barut A, Barut F, Arikan I, Harma M, Harma MI, Ozmen BU: Comparison of the histopathological diagnoses of preoperative dilatation and curettage and hysterectomy specimens. J Obstet Gynaecol Res 2012;38:16-22.
11.
Kazandi M, Okmen F, Ergenoglu AM, Yeniel AO, Zeybek B, Zekioglu O, Ozdemir N: Comparison of the success of histopathological diagnosis with dilatation-curettage and Pipelle endometrial sampling. J Obstet Gynaecol 2012;32:790-794.
12.
Lee DO, Jung MH, Kim HY: Prospective comparison of biopsy results from curettage and hysteroscopy in postmenopausal uterine bleeding. J Obstet Gynaecol Res 2011;37:1423-1426.
13.
Yanoh K: Descriptive reporting format for endometrial cytology. Ver.2012 (abstract, in Japanese). J Jpn Soc Clin Cytol 2012;51 (suppl):218.
14.
Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE: Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004;12:207-223.
15.
Liang SX, Chambers SK, Cheng L, Zhang S, Zhou Y, Zheng W: Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol 2004;12:319-331.
16.
Zheng W, Xiang L, Fadare O, Kong B: A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011;35:e1-e14.
17.
Remondi C, Sesti F, Bonanno E, Pietropolli A, Piccione E: Diagnostic accuracy of liquid-based endometrial cytology in the evaluation of endometrial pathology in postmenopausal women. Cytopathology 2013;24:365-371.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.